期刊文献+

去势抵抗性前列腺癌患者使用醋酸阿比特龙治疗后发生前列腺特异性抗原闪烁现象的相关因素 被引量:3

Related factors of prostate specific antigen flare phenomenon in patients with Castration-resistant prostate cancer after treatment with abiraterone acetate
下载PDF
导出
摘要 目的:分析去势抵抗性前列腺癌(castration-resistant prostate cancer,CRPC)患者应用醋酸阿比特龙联合泼尼松治疗早期出现前列腺特异性抗原闪烁(prostate specific antigen flare,PSA Flare)现象后对患者特异性前列腺抗原(prostate specific antigen,PSA)下降水平和无进展生存时间(progress free sur v ival,PFS)的影响。方法:共纳入2015年10月至2017年10月接受醋酸阿比特龙联合泼尼松治疗的55例CRPC患者,长期随访并记录治疗期间血清PSA等检查资料,动态观察患者疾病变化情况。结果:患者持续有效ADT内分泌治疗时间的不同对PSA Flare的出现有一定的影响。PSA Flare的出现不会影响PSA下降水平,但会在一定程度上积极影响患者达到PSA缓解水平的疗效。PSA Flare的出现对患者的PFS无明显影响。结论:使用醋酸阿比特龙联合泼尼松治疗CRPC患者中,PSA Flare的出现对患者达到PSA缓解具有一定的积极意义。 Objective: To analyze the effect of prostate specific antigen flare(PSA flare) on the level of PSA decline and the progression free survival time of patients with castration-resistant prostate cancer(CRPC) with abiraterone acetate and prednisone acetate in the early stage of treatment. Methods: The clinical data of 55 CRPC patients who were treated with prednisone from October 2015 to October 2017 were enrolled in the study. Long-term follow up and record the prostate specific antigen(PSA) and other data during treatment. Results: The duration of continuous effective endocrine therapy had a certain effect on the occurrence of PSA flare. The occurrence of PSA flare affected the level of PSA decline, but it positively affected the curative effect of PSA to a certain extent. The presence of PSA Flare had no significant effect on PFS in patients. Conclusion: In the treatment of CRPC patients, the presence of PSA Flare has a positive effect on PSA relief.
作者 李俊 杜鸿 熊国兵 廖勇 黄翔 邱明星 LI Jun;DU Hong;XIONG Guobing;LIAO Yong;HUANG Xiang;QIU Mingxing(Department of Urology,Sichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital,Chengdu 610072,China)
出处 《临床与病理杂志》 2018年第6期1228-1233,共6页 Journal of Clinical and Pathological Research
关键词 去势抵抗性前列腺癌 醋酸阿比特龙 前列腺特异性抗原闪烁 PSA缓解率 前列腺特异性抗原 castration-resistant prostate cancer abiraterone acetate prostate specific antigen flare PSA response rate prostate specific antigen
  • 相关文献

参考文献4

二级参考文献43

  • 1赫杰,赵平,陈万青.2011中国肿瘤登记年报.北京:军事医学科学出版社,2012.
  • 2Segi M. Cancer mortality for selected sites in 24 countries ( 1950- 57). Sendai, Japan: Department of Public Health, Tohoku Uni- versity of Medicine: 1960.
  • 3Ferlay J, Shin HR, Bray F, et al. Estimates of worldwide burden of cancer in 2008 : GLOBOCAN 2008. Int J Cancer, 2010, 127 : 2893-2917.
  • 4Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin, 2011, 61 : 69-90.
  • 5Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin, 2012, 62: 10-29.
  • 6Peyromaure M, Debre B, Mao K, et al. Management of prostate cancer in China: a muhicenter report of 6 institutions. J Urol, 2005, 174: 1794-1797.
  • 72012中国肿瘤登记年报[R].
  • 8CANCER REGISTRY ANNUAL REPORT, 2011, Taiwan. HEALTH PROMOTION ADMINISTRATION, MINISTRY OF HEALTH AND WELFARE, Taiwan, February, 2014.
  • 9Kaisary AV, et al. Comparison of LHRH analogue (Zoladex) with orchiectomy in patients with metastatic prostatic carcinoma[J]. Br J Urol 1991,67:502-508.
  • 10James ND, et al. Survival with newly diagnosed metastatic prostate cancer in the "Docetaxel Era" : data from 917 patients in the control arm of the STAMPEDE Trial (MRC PR08, CRUK/06/019) [J]. Eur Urol 2015,67:1028-1038.

共引文献128

同被引文献30

引证文献3

二级引证文献13

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部